SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Phase 3
Completed
- Conditions
- Hepatitis BDiphtheriaPertussisTetanusPoliomyelitisHaemophilus Influenzae Type B Infection
- Interventions
- Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)Biological: Infanrix Hexa™
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 881
- Registration Number
- NCT00654901
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
Phase 2
Completed
- Conditions
- MeningitisMeningococcal Infection
- Interventions
- Biological: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 378
- Registration Number
- NCT00643916
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers
Phase 1
Completed
- Conditions
- MeningitisMeningococcal Infection
- Interventions
- Biological: Meningococcal Polysaccharide Tetanus Protein ConjugateDietary Supplement: Meningococcal polysaccharide group C conjugated
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 360
- Registration Number
- NCT00631995
Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
Phase 2
Completed
- Conditions
- Influenza
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 110
- Registration Number
- NCT00623181
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Phase 2
Completed
- Conditions
- Japanese EncephalitisHepatitis A
- Interventions
- Biological: Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)Biological: Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT00621764
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
Phase 3
Completed
- Conditions
- PolioDiphtheriaHepatitis BPertussis
- Interventions
- Biological: DTaP-IPV-HB-PRP~T vaccine
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 254
- Registration Number
- NCT00619502
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase 2
Terminated
- Conditions
- CancerMelanoma
- Interventions
- Biological: Intron A, Interferon alpha -2bBiological: ALVAC(2) Melanoma multi-antigen therapeutic vaccine
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 23
- Registration Number
- NCT00613509
Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: Inactivated, split-virion influenza virus
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 62
- Registration Number
- NCT00606359
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly
Phase 2
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Inactivated Poliomyelitis vaccine (IMOVAX)
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 236
- Registration Number
- NCT00604058
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td
Phase 4
Completed
- Conditions
- TetanusDiphtheria
- Interventions
- Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3651
- Registration Number
- NCT00601835
© Copyright 2025. All Rights Reserved by MedPath